Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2003

View Archived Issues

EPI-4067: multitargeting antisense oligonucleotide for the treatment of allergic disease and asthma

New anticoccidial agents from fungal origin presented by Meiji Seika and Mitsubishi Chemical

Neurocrine Biosciences identifies novel GnRH antagonists

Nociceptin receptor agonists identified by Banyu researchers

Nikken Chemicals presents new antiasthmatic compound with dual mechanism

Novel nicotinic receptor modulators and their use as peripheral analgesics

Pyrazole ERK/Akt kinase inhibitors prepared and tested at Vertex

Merck scientists describe tissue-selective androgen receptor modulators for bone disorders

New androgen receptor modulators and their use in age-related conditions reported by BMS

NSAIDs shown to bind to beta-amyloid senile plaques in vitro

SR-13668 selected by NCI for RAPID program

P57 program progresses at Pfizer

Romark launches Alinia for children in U.S.

Phase II Alista trial begins recruitment

FDA approves expanded label for Betaseron; ABOVE trial explores increased dose and frequency

Phase III decitabine study in MDS completes patient enrollment

Results reported for phase III trial of Affinitak in NSCLC

H3 Pharma licenses SC-1 from OncoMab

Further analysis of DIAMOND study data reported

Phase I IND for AVP-13358 cleared

Dual erbB-2/EGFR tyrosine kinase inhibitor with promising preclinical profile

Toxicity of LE-SN-38 in dogs after repeated i.v. doses

Acute and subchronic toxicity testing conducted on CJC-1131 in rats and dogs

Calmodulin antagonist DY-9760e improves brain edema by inhibiting enhanced BBB permeability

One course of AIC immunotherapy lasts through two allergy seasons according to phase II data

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...